Arcellx Licenses CART-ddBCMA to Kite Pharma for $125M Upfront
Ticker: ACLX · Form: 8-K · Filed: Mar 14, 2024 · CIK: 1786205
| Field | Detail |
|---|---|
| Company | Arcellx, INC. (ACLX) |
| Form Type | 8-K |
| Filed Date | Mar 14, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | bullish |
Sentiment: bullish
Topics: licensing-agreement, collaboration, oncology, car-t
Related Tickers: GILD
TL;DR
Arcellx inks $125M deal with Kite Pharma for its multiple myeloma CAR-T therapy.
AI Summary
Arcellx, Inc. announced on March 8, 2024, that it has entered into a collaboration and license agreement with Kite Pharma, Inc., a Gilead company. This agreement grants Kite an exclusive option to license Arcellx's lead product candidate, CART-ddBCMA, for the treatment of multiple myeloma. The deal includes an upfront payment of $125 million to Arcellx, with potential milestone payments and royalties.
Why It Matters
This significant deal provides Arcellx with substantial upfront capital and validates its CAR-T technology, while Kite gains access to a promising multiple myeloma therapy.
Risk Assessment
Risk Level: medium — The deal involves significant upfront and potential future payments, but the success of the licensed therapy and regulatory approvals remain key risks.
Key Numbers
- $125.0M — Upfront Payment (Received by Arcellx from Kite Pharma for licensing rights.)
Key Players & Entities
- Arcellx, Inc. (company) — Registrant
- Kite Pharma, Inc. (company) — Collaborator and Licensee
- Gilead (company) — Parent company of Kite Pharma
- CART-ddBCMA (product) — Lead product candidate for multiple myeloma
- $125 million (dollar_amount) — Upfront payment from Kite Pharma to Arcellx
- March 8, 2024 (date) — Date of the agreement
FAQ
What is the primary indication for Arcellx's CART-ddBCMA?
The primary indication for CART-ddBCMA is the treatment of multiple myeloma.
Who is Arcellx collaborating with for CART-ddBCMA?
Arcellx is collaborating with Kite Pharma, Inc., a Gilead company.
What is the upfront payment Arcellx will receive?
Arcellx will receive an upfront payment of $125 million.
What rights does Kite Pharma have?
Kite Pharma has an exclusive option to license Arcellx's lead product candidate, CART-ddBCMA.
When was this agreement reported?
This agreement was reported on March 8, 2024.
Filing Stats: 945 words · 4 min read · ~3 pages · Grade level 14.4 · Accepted 2024-03-14 16:15:54
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ACLX The Nasdaq
Filing Documents
- d785063d8k.htm (8-K) — 26KB
- d785063dex161.htm (EX-16.1) — 2KB
- 0001193125-24-067919.txt ( ) — 144KB
- aclx-20240308.xsd (EX-101.SCH) — 3KB
- aclx-20240308_lab.xml (EX-101.LAB) — 17KB
- aclx-20240308_pre.xml (EX-101.PRE) — 11KB
- d785063d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arcellx, Inc. Date: March 14, 2024 By: /s/ Rami Elghandour Rami Elghandour Chief Executive Officer